MicroRNA-based therapeutics and nanomedicine for brain tumour treatment

miRNAs are key cell regulatory elements code by the genome. Although their signature in cancer is incompletely known and not yet an element of diagnosis, the role of oncomiRs become increasingly documented. Alongside cancer intrinsic signals in which they exert essential functions, miRNAs are also responding to environmental cues. Developing novel approaches to target miRNA-pathways represents a pivotal issue in research and may result in a major breakthrough for human health. Due to their submicron size and versatile physicochemical properties the emergence of innovative nanomedicines may be here largely advantageous for the development of targeted clinical strategies. With a special focus on glioblastoma, the present review addresses cancer functions of miRNAs and raises the question of an adapted nanomedicine.